Improving the Design of Clinical Trials of Drugs to Treat Schizophrenia

Based on their analyses of schizophrenia drug trials submitted by drug developers, CDER researchers have identified ways in which these trials could be streamlined while not compromising their sensitivity.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news